The healthcare software specialist CompuGroup Medical has received a significant takeover offer from private equity firm CVC Capital Partners, valuing the company at approximately 1.2 billion euros with a share price of 22 euros. This development triggered a remarkable stock price surge of over 31 percent, pushing shares to 21.66 euros. The proposed deal structure maintains the founding family’s majority stake of 50.1 percent while CVC aims to acquire a minimum 17 percent shareholding. Following the successful completion of this transaction, expected in the first half of 2025, plans are in place to delist the company from the stock exchange.
Market Assessment
Investment bank Berenberg has adjusted its Rating for CompuGroup Medical from „Buy“ to „Hold,“ while marginally raising its price target from 21 to 22 euros in response to the takeover bid. The offer, which comes with support from the founding family, management, and supervisory board, represents a pivotal moment for the company. Despite offering a double-digit percentage premium over previous valuations, some investors who positioned themselves before July’s profit warning might find the offer less attractive than anticipated.
Ad
CompuGroup Medical Stock: New Analysis – 12 December
Fresh CompuGroup Medical information released. What’s the impact for investors? Our latest independent report examines recent figures and market trends.
Read our updated CompuGroup Medical analysis…
The healthcare software specialist CompuGroup Medical has received a significant takeover offer from private equity firm CVC Capital Partners, valuing the company at approximately 1.2 billion euros with a share price of 22 euros. This development triggered a remarkable stock price surge of over 31 percent, pushing shares to 21.66 euros. The proposed deal structure maintains the founding family’s majority stake of 50.1 percent while CVC aims to acquire a minimum 17 percent shareholding. Following the successful completion of this transaction, expected in the first half of 2025, plans are in place to delist the company from the stock exchange.
Market Assessment
Investment bank Berenberg has adjusted its Rating for CompuGroup Medical from „Buy“ to „Hold,“ while marginally raising its price target from 21 to 22 euros in response to the takeover bid. The offer, which comes with support from the founding family, management, and supervisory board, represents a pivotal moment for the company. Despite offering a double-digit percentage premium over previous valuations, some investors who positioned themselves before July’s profit warning might find the offer less attractive than anticipated.
Ad
Fresh CompuGroup Medical information released. What’s the impact for investors? Our latest independent report examines recent figures and market trends.